Author Topic: (Abst.) Phase 2b trial comparing 3 neuroprotective drugs in SPMS  (Read 27 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8218
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Phase 2b trial comparing 3 neuroprotective drugs in SPMS
« on: September 01, 2018, 12:24:30 pm »
From PubMed, September 1, 2018--the announcement of a new study, "Multiple sclerosis--secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in SPMS."


The drugs are "amiloride (acid-sensing ion channel antagonist); fluoxetine (selective serotonin reuptake inhibitor); and riluzole (glutamate antagonist)."  Fluoxetine is also known as Prozac or Sarafem. Miloride's brand name is Midamor. Riluzole is marketed as Rilutek and Teglutik and has been used to treat ALS (amyotrophic lateral sclerosis).


https://www.ncbi.nlm.nih.gov/pubmed/30166303
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
49 Views
Last post August 07, 2016, 09:34:11 am
by agate
0 Replies
45 Views
Last post September 17, 2016, 06:43:41 am
by agate
0 Replies
83 Views
Last post August 09, 2017, 06:07:31 am
by agate
0 Replies
24 Views
Last post September 14, 2018, 02:34:14 pm
by agate
0 Replies
31 Views
Last post September 30, 2018, 07:31:15 pm
by agate